TokenPost·
Biogen’s Diranersen Data Show Slower Alzheimer’s Decline Over Two Years

The Phase 2 open-label extension showed a 38% improvement in clinical benefit with a 60 mg regimen given twice yearly.
Every crypto headline. One feed. Updated every minute.

The Phase 2 open-label extension showed a 38% improvement in clinical benefit with a 60 mg regimen given twice yearly.